

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 29 April 2015** – On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.

Under the programme initiated 30 January 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 30 January 2015 to 28 April 2015. The programme is now concluded.

Since the announcement as of 22 April 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
<b>Accumulated, last announcement</b>	<b>10,425,481</b>		<b>3,406,342,971</b>
22 April 2015	150,000	392.09	58,812,750
23 April 2015	153,000	388.64	59,461,691
24 April 2015	150,000	391.01	58,652,235
27 April 2015	150,000	395.18	59,276,970
28 April 2015	149,423	384.50	57,453,054
<b>Accumulated under the programme</b>	<b>11,177,904</b>		<b>3,699,999,671</b>

With the transactions stated above, Novo Nordisk owns a total of 19,816,756 B shares of DKK 0.20, corresponding to 0.8% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2015. As of 21 April 2015, Novo Nordisk has repurchased a total of 11,177,904 B shares equal to a transaction value of DKK 3,699,999,671.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)*

### **Further information**

#### *Media:*

Anne Margrethe Hauge	+45 3079 3450	<a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a>
----------------------	---------------	--

#### *Investors:*

Kasper Roseeuw Poulsen	+45 3079 4303	<a href="mailto:krop@novonordisk.com">krop@novonordisk.com</a>
Daniel Bohsen	+45 3079 6376	<a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a>
Melanie Raouzeos	+45 3075 3479	<a href="mailto:mrz@novonordisk.com">mrz@novonordisk.com</a>
Frank Daniel Mersebach (US)	+1 609 235 8567	<a href="mailto:fdni@novonordisk.com">fdni@novonordisk.com</a>